Search
Selected Filter
Filter Results
Displaying 21–30 of 396 diseases results
-
Feb 23, 2024
Eye on the Cure Podcast | Episode 62: Dr. Peter Quinn
Peter Quinn, PhD, a principal investigator and associate research scientist at Columbia University, talks to host Ben Shaberman about the promise of emerging CRISPR/Cas9 gene editing therapies, including base and prime editing approaches, for inherited retinal diseases. Dr. Quinn also reviews gene editing projects ongoing in his lab for patients with mutations in CRB1 and PRPH2.
-
Feb 21, 2024
jCyte Announces Plans to Launch Phase 3 Clinical Trial of Cell Therapy for RP
Known as retinal progenitors, the company’s jCells® are designed to preserve photoreceptors in people with retinitis pigmentosa (RP) and other retinal diseases.
-
Feb 9, 2024
The company plans to begin a Phase 2/3 clinical trial for the treatment during the first half of 2024.
-
Feb 6, 2024
Foundation Fighting Blindness Launches GYROS, a Natural History Study for People with Gyrate Atrophy
Gyrate atrophy is an inherited retinal disease—causing progressive vision loss. GYROS results will help researchers design clinical trials for an emerging gyrate atrophy gene therapy.
-
Feb 5, 2024
Foundation’s Reach Inspires Partnership for Nixon Family
After Janine’s diagnosis of an IRD caused by a mutation of the PRPH2 gene, she and her husband set out to learn and help all they could. So they started working with the Foundation Fighting Blindness and have launched the ‘PRPH2 and Associated Retinal Degenerations Program.’
-
Feb 1, 2024
Ascidian to Launch Clinical Trial for Stargardt Disease RNA Editing Therapy
ACDN-01 is the only genetic medicine entering clinical development for Stargardt disease.
-
Dec 11, 2023
Known as antisense oligonucleotides, the treatments performed encouragingly in ProQR’s clinical trials
-
Nov 13, 2023
IRD Community Loses Usher Syndrome Research Trailblazer William Kimberling, PhD
Dr. Kimberling helped discover the identification and characterization of several genes that cause Usher syndrome.
-
Nov 8, 2023
Kiora Reports Vision Restoration in Phase 1/2 Clinical Trial for Photoswitch Therapy
The company’s molecule is designed to restore some vision to people with ultra-low or no vision caused by advanced retinitis pigmentosa and other retinal diseases.
-
Nov 6, 2023
NY Researcher’s App Transforms Commuting for the Visually Impaired
John-Ross Rizzo, a dedicated New York-based researcher, was confronted with life-altering news at a young age when he was diagnosed with choroideremia. Driven by the obstacles he faced due to his condition, he now stands as a key figure leading the development of advanced assistive technology, with the goal of reshaping the daily commutes of those with low vision and blindness.